Advertisement

Bilateral adrenal hemorrhage: A rare presentation of catastrophic anti-phospholipid syndrome

Published:August 28, 2022DOI:https://doi.org/10.1016/j.amjms.2022.08.010

      Abstract

      Catastrophic anti-phospholipid syndrome (CAPS) is characterized by microvascular thrombosis in multiple sites leading to multi-organ damage. It is a rare and fatal complication of antiphospholipid syndrome (APS). We present a rare case of CAPS that presented with bilateral (b/l) adrenal hemorrhage making the diagnosis challenging in this otherwise rare disease. A 51-year-old female was initially admitted with abdominal pain and found to have bilateral adrenal hemorrhage. Patient had a fulminant disease course in which she had thrombotic manifestations involving multiple organ systems. This case was especially challenging as the patient's bilateral adrenal hemorrhage was the first manifestation of CAPS; the diagnosis of APS had to be made while treatment for presumed CAPS was emergently commenced for this life-threatening disease. Key to managing this condition is having a high index of suspicion for the diagnosis in patients presenting with multi-organ failure and multiple thromboses and hemorrhage.

      Key Indexing Terms

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of the Medical Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Erkan D
        • Lockshin MD.
        Anti-phospholipid syndrome.
        in: Salmon JE Kelley & Firestein's Textbook of Rheumatology. 10th ed. Elsevier, 2016: 1389-1400
        • Aguiar CL
        • Erkan D.
        Catastrophic antiphospholipid syndrome: how to diagnose a rare but highly fatal disease.
        Therapeut Adv Musculoskelet Dis. 2013; 5: 305-314
        • Cervera R
        • Bucciarelli S
        • Plasín MA
        • et al.
        Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of a series of 280 patients from the “CAPS REGISTRY.
        J Autoimmun. 2009; 32: 240-245
        • Segkos K
        • Short T
        • Ing SW.
        Adrenal hemorrhage due to hypercoagulable state mimicking pheochromocytoma.
        J Clin Translat Endocrinol. 2018; 8: 9-12
        • Aldaajani H
        • Albahrani S
        • Saleh K
        • et al.
        Bilateral adrenal hemorrhage in antiphospholipid syndrome.
        Saudi Med J. 2018; 39: 829-833
        • Cervera R
        • Rodríguez-Pintó I
        • Espinosa G.
        The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: a comprehensive review.
        J Autoimmun. 2018; 92: 1-11
        • Nayer A
        • Ortega LM.
        Catastrophic antiphospholipid syndrome: a clinical review.
        J Nephropathol. 2014; 3: 9-17
        • Kazzaz NM
        • McCune WJ
        • Knight JS
        Treatment of catastrophic antiphospholipid syndrome.
        Curr Opin Rheumatol. 2017; 28: 218-227https://doi.org/10.1097/BOR.0000000000000269
        • Benjume BL
        • Rodriquez-Pinto I
        • Amigo MC
        • et al.
        Eculizumab use in catastrophic antiphospholipid syndrome (CAPS): descriptive analysis from the “CAPS Registry”.
        Autoimmun Rev. 2022; 21: 103055https://doi.org/10.1016/j.autrev.2022.103055
        • Espinosa G
        • Berman H
        • Cervera R
        Management of refractory cases of catastrophic antiphospholipid syndrome.
        Autoimmun Rev. 2011; 10: 664-668https://doi.org/10.1016/j.autrev.2011.04.031
        • Berman H
        • Rodríguez-PintóI
        • Cervera R
        • et al.
        Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab.
        Autoimmun Rev. 2013; 12: 1085-1090https://doi.org/10.1016/j.autrev.2013.05.004